Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + bortezomib + Y-90 ibritumomab tiuxetan
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination regimen consisting of three agents: rituximab, bortezomib, and Y-90 ibritumomab tiuxetan. Rituximab is a monoclonal antibody targeting the CD20 antigen on B lymphocytes, leading to cell lysis primarily via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Bortezomib is a small molecule proteasome inhibitor that disrupts protein degradation pathways in cancer cells, resulting in apoptosis. Y-90 ibritumomab tiuxetan (Zevalin) is a radioimmunoconjugate composed of an anti-CD20 monoclonal antibody (ibritumomab) linked to the radioactive isotope yttrium-90; it delivers targeted radiation to CD20-positive B-cells, inducing cell death through both immunologic and radiologic mechanisms. This combination has been investigated for relapsed or refractory follicular non-Hodgkin lymphoma and other B-cell lymphomas[1][2][3][4][5].
- Other names
- yttrium Y 90 ibritumomab tiuxetanyttrium-90 ibritumomab tiuxetanyttrium90 ibritumomab tiuxetanyttrium 90 ibritumomab tiuxetan
02
Targets
Beyond the preview
Go deeper on rituximab + bortezomib + Y-90 ibritumomab tiuxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + bortezomib + Y-90 ibritumomab tiuxetan.